The Hippo‐signaling effector YAP1 was recently found to compensate for oncogenic RAS in certain neoplasms, suggesting so far unanticipated molecular interplays between these major signaling routes. A new study in this issue of The EMBO Journal details KRAS‐dependent control of YAP1 stability as well as positive feedback regulation via the RAS/YAP1/EGFR‐ligand axis as novel molecular mechanisms that could become exploitable for therapeutic strategies.
The RAS and YAP1 dance, who is leading?
CORBO, Vincenzo;
2014-01-01
Abstract
The Hippo‐signaling effector YAP1 was recently found to compensate for oncogenic RAS in certain neoplasms, suggesting so far unanticipated molecular interplays between these major signaling routes. A new study in this issue of The EMBO Journal details KRAS‐dependent control of YAP1 stability as well as positive feedback regulation via the RAS/YAP1/EGFR‐ligand axis as novel molecular mechanisms that could become exploitable for therapeutic strategies.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Corbo_EmboJ.pdf
non disponibili
Licenza:
Dominio pubblico
Dimensione
155.69 kB
Formato
Adobe PDF
|
155.69 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
